2022 年第三季度报告 证券代码：605033 证券简称：美邦股份 陕西美邦药业集团股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 2022 年第三季度报告 | 经营活动产生的现 | 不适用 不适用 | | | -25,016,421.51 | | 89.23% | | | --- | --- | --- | --- | --- | --- | --- | --- | | 金流量净额 | | | | | | | | | 基本每股收益（元/ | -0.04 | | 32.57% | 0.82 | | 30.98% | | | 股） | | | | | | | ...

陕西美邦药业集团股份有限公司 2022 年半年度报告 公司代码：605033 公司简称：美邦股份 陕西美邦药业集团股份有限公司 2022 年半年度报告 1 / 182 陕西美邦药业集团股份有限公司 2022 年半年度报告 重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实 性、准确性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人张少武、主管会计工作负责人何梅喜及会计机构负责人（会计主管人 员）何梅喜声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中涉及的未来发展计划、发展战略等前瞻性陈述不构成公司对投资者的 实质承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划 、预测与承诺之间的差异，请投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 ...

Financial Performance - The company's operating revenue for Q1 2022 was CNY 487,555,601.85, representing a year-on-year increase of 77.56%[5] - The net profit attributable to shareholders for the same period was CNY 91,752,261.05, up 96.99% compared to the previous year[5] - Basic and diluted earnings per share were both CNY 0.68, reflecting a growth of 47.53% year-on-year[6] - The total profit for Q1 2022 was ¥106,934,436.60, up from ¥54,957,683.45 in the same period last year, indicating a growth of 94.3%[20] - The operating profit for Q1 2022 reached ¥106,982,851.88, compared to ¥54,724,946.64 in Q1 2021, reflecting an increase of 95.5%[22] - The net profit attributable to shareholders of the parent company for Q1 2022 was ¥91,752,261.05, compared to ¥46,576,192.23 in Q1 2021, representing an increase of 96.7%[20] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,446,430,467.04, a decrease of 1.16% from the end of the previous year[6] - Total assets as of March 31, 2022, were ¥1,446,430,467.04, slightly down from ¥1,463,381,113.31 at the end of 2021[16] - Total liabilities decreased to ¥387,725,822.77 from ¥496,428,730.09, a decline of 22%[16] - The company's equity attributable to shareholders increased to ¥1,058,704,644.27 from ¥966,952,383.22, reflecting a growth of 9.5%[16] Cash Flow - The company's cash flow from operating activities was negative at CNY -81,768,900.40, indicating a significant cash outflow[5] - The cash flow from operating activities for Q1 2022 was a net outflow of ¥81,768,900.40, an improvement from a net outflow of ¥126,499,568.84 in Q1 2021[22] - The cash flow from investing activities generated a net inflow of ¥13,871,427.04 in Q1 2022, compared to a net outflow of ¥33,019,410.87 in Q1 2021[23] - The total cash and cash equivalents at the end of Q1 2022 were ¥91,338,101.17, significantly up from ¥19,793,671.70 at the end of Q1 2021[23] Expenses - Total operating costs for Q1 2022 were ¥361,683,622.68, up 71.8% from ¥210,667,507.00 in Q1 2021[18] - Research and development expenses rose by 94.81%, reflecting increased investment in R&D[7] - Research and development expenses for Q1 2022 were ¥25,662,200.89, up from ¥13,173,234.98 in Q1 2021, marking a rise of 94.5%[22] - The company reported a significant increase in sales expenses by 205.31%, attributed to higher sales activities[7] - The company reported a decrease in financial expenses, with interest expenses of ¥151,987.12 in Q1 2022, compared to ¥112,152.77 in Q1 2021, indicating a rise of 35.4%[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 14,797[9] Market Strategy - The company is focusing on expanding its market presence and enhancing product development, although detailed strategies were not specified in the report[18]

Financial Performance - The company's operating revenue for 2021 was CNY 842,490,330.97, representing a 48.19% increase compared to CNY 568,518,122.56 in 2020[22] - The net profit attributable to shareholders for 2021 was CNY 125,742,881.24, a 59.71% increase from CNY 78,734,291.94 in the previous year[22] - The net profit after deducting non-recurring gains and losses was CNY 111,061,265.71, up 48.82% from CNY 74,630,108.05 in 2020[22] - The net cash flow from operating activities was negative CNY 108,753,545.63, a decrease of 245.25% compared to CNY 74,875,302.08 in 2020[22] - The net assets attributable to shareholders increased by 115.18% to approximately CNY 966.95 million compared to the end of 2020[23] - Total assets rose by 86.21% to approximately CNY 1.46 billion compared to the end of 2020[23] - Basic earnings per share increased by 46.15% to CNY 1.14 from CNY 0.78 in 2020[24] - The gross profit margin improved by 1.73 percentage points to 38.29%, driven by higher sales of new products[66] - The company reported a significant increase in financing activities, with net cash flow from financing activities reaching CNY 350.59 million, a rise of 687.26%[63] Dividend and Shareholder Information - The company plans to distribute a cash dividend of CNY 1.9 per 10 shares, totaling CNY 25,688,000.00 based on a total share capital of 135,200,000 shares[5] - The total number of shares held by the board members remained unchanged at 76,000,000 shares throughout the reporting period[154] - The total pre-tax remuneration for the board members amounted to 4.97 million yuan, with individual remuneration ranging from 19.6 thousand to 75 thousand yuan[154] - The company has not proposed any cash profit distribution plan despite having positive distributable profits, indicating a focus on reinvestment[179] Risk Management and Compliance - The company has not reported any significant risks that could materially affect its operations during the reporting period[8] - The company emphasizes the importance of understanding the risks associated with forward-looking statements regarding future development plans and strategies[6] - The company has maintained a high level of transparency in information disclosure, adhering to the regulations set forth by the China Securities Regulatory Commission[148] - The company has developed a comprehensive internal control mechanism to enhance governance and risk management awareness among its directors and senior management[149] - The company has not encountered any significant differences in governance compared to the regulations set by the China Securities Regulatory Commission[149] Research and Development - Research and development expenses amounted to 63.81 million yuan, a 24.22% increase year-on-year, representing 7.57% of total revenue[38] - The number of R&D personnel was 186, accounting for 20.02% of the total workforce[73] - The company has established partnerships with several universities, including China Agricultural University and Zhejiang University, to enhance its R&D capabilities in pesticide products[97] - The company has implemented a multi-departmental approach to its R&D innovation process, ensuring that market demands guide product development[94] - The company aims to enhance its market competitiveness by increasing R&D investment and developing new products, focusing on high-efficiency, low-toxicity, and environmentally friendly products[123] Market Position and Strategy - The company aims to enhance its market position by focusing on high-quality development and expanding its agricultural protection product line[34] - The company has been ranked among the top 20 in China's pesticide industry formulation sales for four consecutive years since 2017[47] - The company emphasizes a dual-drive strategy of raw pesticide and formulation integration, aiming for both domestic and international market expansion[51] - The company has established a nationwide marketing channel, enhancing its ability to reach diverse agricultural regions[57] - The company is committed to establishing a modern active ingredient production base to strengthen its position in the agricultural supply chain[125] Environmental Responsibility - The company has implemented effective pollution control measures, achieving compliance with emission standards for waste gas and wastewater during the reporting period[188] - The company has a valid pollution discharge permit until December 27, 2025, and has established a comprehensive risk management system[187] - The company has implemented effective comprehensive treatment measures for waste water, waste gas, waste residue, and noise, and has obtained the environmental management system certification[196] - The company has not experienced any major violations of environmental laws or regulations, nor any pollution accidents during the reporting period[194] Corporate Governance - The board of directors convened 15 meetings, with a composition of 9 members, including 3 independent directors, adhering to relevant laws and regulations[145] - The supervisory board conducted 7 meetings, effectively overseeing the company's management and financial status[147] - The company has established an independent financial accounting department and a strict financial management system, ensuring no shared bank accounts with controlling shareholders[151] - The company has a complete and independent business system, with no interference from controlling shareholders in its operations[151] Employee and Management Structure - The company employed a total of 933 staff members, with 346 in the parent company and 587 in major subsidiaries[172] - The workforce includes 220 production personnel, 433 sales personnel, 186 technical personnel, 27 financial personnel, and 67 administrative personnel[172] - The company is enhancing its talent development plan by establishing a structured talent pipeline and focusing on training to improve management and technical skills[131] - The company has a diverse management team with experience in various sectors, including agriculture, finance, and pharmaceuticals[156] Challenges and Market Conditions - The company faced challenges due to rising raw material prices and implemented strategies to minimize procurement costs[46] - The company recognizes the seasonal nature of its business, with peak pesticide demand typically occurring from March to September, and is working to mitigate the impact of this seasonality on cash flow management[138] - The company faces market competition risks due to a large number of small-scale pesticide producers and a lack of strong R&D capabilities, leading to product homogeneity and price-based competition[135]